Metrics as of 10/16/2026, 05:20 AM (Berlin time), refresh in progress.
Pulse Biosciences Stock
Pulse Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Paul Arthur LaViolette
- Employees
- 116
- Market cap
- $3.2 B
- IPO
- 18/05/2016
Pulse Biosciences, Inc. is a healthcare company specializing in bioelectric medicine. The primary offering of the firm is the CellFX System, which is a sophisticated, console-based platform precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Pulse Biosciences stock: price history
1D
-1.6%
1W
-8.8%
1M
-17.4%
6M
+122.3%
YTD
+232.0%
1Y
+163.7%
2Y
+178.2%
5Y
+110.6%
10Y
+706.9%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~33% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Pulse Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Pulse Biosciences is a medical device company specializing in bioelectronics. The company offers the CellFX System, a software-controlled platform for treating various medical indications. The platform utilizes proprietary Nano-Pulse Stimulation technology, which selectively eliminates target cells through extremely short electrical pulses without damaging surrounding tissue through thermal effects.
- Revenue model
- Hardware sales
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Pulse Biosciences
Analyst assessment of Pulse Biosciences
PRICE TARGET LOW
US$55.00
CONSENSUS
US$60.20
MEDIAN
US$58.00
PRICE TARGET HIGH
US$70.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 13/10/2026
Pulse Biosciences stock metrics
P/E
-38.97
P/B
31.71
EV/EBITDA
-39.66
RETURN ON EQUITY
-24.8%
NET MARGIN
-5,681.3%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
18.5%
FLOAT SHARES
13,160,595
AVG. DAILY VOLUME (30D)
579,750
Insider transactions (SEC)
Teplitsky Liane Rae
Teplitsky Liane Rae
Teplitsky Liane Rae
Teplitsky Liane Rae
DUGGAN ROBERT W
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.6%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Pulse Biosciences stock
What does Pulse Biosciences do?
Pulse Biosciences, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Paul Arthur LaViolette, the company employs around 116 people.
The IPO was on 18/05/2016; the stock trades on NASDAQ under the ticker PLSE.
What do analysts say about Pulse Biosciences stock?
6 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$60.20, ranging from US$55.00 to US$70.00, with a median of US$58.00.
This is an external assessment, not a statement by Market Jury.
When does Pulse Biosciences report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Pulse Biosciences pay a dividend?
No, Pulse Biosciences currently does not pay a dividend.
Which stocks are comparable to Pulse Biosciences?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Pulse Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pulse Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.